Skip to main content
Log in

Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance

  • Consensus Document
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Cardiovascular diseases still represent the leading cause of mortality and hospitalization, particularly in Western countries. As a consequence of the marked changes observed on the demographic characteristics of the general population, the improved survival rate after an acute cardiovascular event, and the progressive rise of costs (mostly due to technological and pharmacological innovations), the estimated burden of cardiovascular diseases will soon become insurmountable for national healthcare systems. In this view, an integrated approach aimed at improving strategies for cardiovascular disease prevention and, thus, limiting the negative outcomes, would probably be successful. Such an approach may not only achieve long-term benefits, but even significant advantages in the short to medium term, mostly in asymptomatic high-risk individuals. Indeed, this latter population of asymptomatic high-risk individuals would mostly benefit from extensive application and improvement of strategies for cardiovascular disease prevention with a favourable cost-benefit ratio.

The Italian Society for Cardiovascular Disease Prevention — Società Italiana per la Prevenzione Cardiovascolare (SIPREC) — has recognized this strategic aim, focusing a vast majority of its institutional action on the effort for providing educational supports and consensus documents, which represent an overview of the scientific knowledge and personal clinical expertise by national and international key opinion leaders. Expert committees periodically generate ‘state-of-the-art’ documents on specific scientific topics with relevant socioeconomic implications and large clinical impact. The present article is dedicated to healthcare professionals, and is based on the available evidence, and provides useful information on diagnostic algorithms and therapeutic options. In 2006, the SIPREC Scientific Committee promoted a consensus document on the metabolic syndrome,[1] which is still widely used, frequently cited and updated, from which originated a broad educational programme throughout the Italian territory. This programme has certainly contributed to improving knowledge of a widespread clinical condition, such as the metabolic syndrome, which SIPREC interpreted not only as a theoretical pathophysiological concept or a nosographic entity, but rather as a real clinical tool for identifying and ‘intercepting’ those asymptomatic individuals at risk of cardiovascular events, before the estimated level of risk becomes high.

This new article may be viewed in the same strategic line. The relationship between abnormalities in blood glucose metabolism (or dysglycaemia) and cardiovascular complications represents another important and relatively early target for cardiovascular disease prevention. SIPREC Scientific Committee identified even in this clinical setting an excellent group of scientific experts, in order to collect a multidisciplinary ‘task force’. This group has been asked to explain in a short, simple and effective fashion the epidemiological impact and the pathophysiological nature of the problem, its clinical features, potential diagnostic algorithms and therapeutic options, and its influence on the clinical practice of both specialist physicians and general practitioners.

The work of this Task Force, which is reported in this article, is primarily a baseline for discussing novel future strategies for cardiovascular prevention. Also, this article is aimed at highlighting the importance of an emerging marker of cardiovascular risk, which is little recognized and often undervalued. Dysglycaemia, in turn, has a clinical significance, which is at least, in part, comparable with that of type 2 diabetes mellitus, both in terms of epidemiological prevalence and of long-term cardiovascular prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Sesti G, Volpe M, Cosentino F, et al. Metabolic syndrome: diagnosis and clinical management, an Official Document of the Working Group of the Italian Society of Cardiovascular Prevention (SIPREC). High Blood Press Cardiovasc Prev 2006; 13(4): 185–98

    Article  CAS  Google Scholar 

  2. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 Jun 12; 358(24): 2545–59

    Article  PubMed  CAS  Google Scholar 

  3. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 Jun 12; 358(24): 2560–72

    Article  PubMed  CAS  Google Scholar 

  4. Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997 Jan 27; 157(2): 181–8

    Article  PubMed  CAS  Google Scholar 

  5. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 Dec 22; 353(25): 2643–53

    Article  PubMed  Google Scholar 

  6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 Sep 12; 317 (7160): 703–13

  7. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 Jan 30; 348(5): 383–93

    Article  PubMed  Google Scholar 

  8. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 Feb 7; 358(6): 580–91

    Article  PubMed  CAS  Google Scholar 

  9. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ 1998 Aug 8; 317 (7155): 371–5

  10. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006 May; 29(5): 1130–9

    Article  PubMed  CAS  Google Scholar 

  11. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007 Dec; 78(3): 305–12

    Article  PubMed  Google Scholar 

  12. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007 Mar; 30(3): 753–9

    Article  PubMed  CAS  Google Scholar 

  13. Danaei G, Lawes CM, Vander Hoorn S, et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006 Nov 11; 368(9548): 1651–9

    Article  PubMed  Google Scholar 

  14. Bartnik M, Norhammar A, Ryden L. Hyperglycaemia and cardiovascular disease. J Intern Med 2007 Aug; 262(2): 145–56

    Article  PubMed  CAS  Google Scholar 

  15. Bianchi C, Miccoli R, Penno G, et al. Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care 2008 Feb; 31Suppl. 2: S208–14

    Article  PubMed  Google Scholar 

  16. Crandall JP, Knowler WC, Kahn SE, et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008 Jul; 4(7): 382–93

    Article  PubMed  Google Scholar 

  17. Standards of medical care in diabetes — 2010. Diabetes Care 2010 Jan; 33 Suppl. 1: S11–61

  18. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 Jan; 28(1): 88–136

    Article  PubMed  CAS  Google Scholar 

  19. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003 Mar; 26 (3): 688–96

  20. Vanuzzo D, Pilotto L, Uguccioni M, et al. Cardiovascular epidemiology: trends of risk factors in Italy. Ital Heart J 2004 Nov; 5Suppl. 8: 19S–27S; discussion 33S–4, 116S–21S

    Google Scholar 

  21. Maggi S, Noale M, Gallina P, et al. Metabolic syndrome, diabetes, and cardiovascular disease in an elderly Caucasian cohort: the Italian Longitudinal Study on Aging. J Gerontol A Biol Sci Med Sci 2006 May; 61(5): 505–10

    Article  PubMed  Google Scholar 

  22. Mannucci E, Monami M, Rotella CM. How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. Nutr Metab Cardiovasc Dis 2007 Dec; 17(10): 719–26

    Article  PubMed  CAS  Google Scholar 

  23. Miccoli R, Bianchi C, Odoguardi L, et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005 Aug; 15(4): 250–4

    Article  PubMed  Google Scholar 

  24. Irace C, Cortese C, Fiaschi E, et al. Components of the metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure. Hypertension 2005 Apr; 45(4): 597–601

    Article  PubMed  CAS  Google Scholar 

  25. Garancini MP, Calori G, Ruotolo G, et al. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia 1995 Mar; 38(3): 306–13

    Article  PubMed  CAS  Google Scholar 

  26. Cicero AF, Dormi A, Nascetti S, et al. Relative role of major risk factors for type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabet Med 2005 Sep; 22(9): 1263–6

    Article  PubMed  CAS  Google Scholar 

  27. Vaccaro O, Riccardi G. Changing the definition of impaired fasting glucose: impact on the classification of individuals and risk definition. Diabetes Care 2005 Jul; 28(7): 1786–8

    Article  PubMed  CAS  Google Scholar 

  28. Barbagallo CM, Cavera G, Sapienza M, et al. Prevalence of overweight and obesity in a rural southern Italy population and relationships with total and cardiovascular mortality: the Ventimiglia di Sicilia project. Int J Obes Relat Metab Disord 2001 Feb; 25(2): 185–90

    Article  PubMed  CAS  Google Scholar 

  29. Noto D, Barbagallo CM, Cefalu AB, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 2008 Mar; 197(1): 147–53

    Article  PubMed  CAS  Google Scholar 

  30. Bonora E, Kiechl S, Willeit J, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004 Jul; 53(7): 1782–9

    Article  PubMed  CAS  Google Scholar 

  31. Vaccaro O, Ruffa G, Imperatore G, et al. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care 1999 Sep; 22(9): 1490–3

    Article  PubMed  CAS  Google Scholar 

  32. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008 Jan; 31 Suppl. 1: S55–60

  33. Standards of medical care in diabetes — 2008. Diabetes Care 2008 Jan; 31 Suppl. 1: S12–54

  34. Fowler G. The teaching of preventive medicine: the role of the primary health care team. J R Soc Med 1986 Nov; 79(11): 633–6

    PubMed  CAS  Google Scholar 

  35. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999 Jan 9; 353(9147): 89–92

    Article  PubMed  CAS  Google Scholar 

  36. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000 Dec 19; 102(25): 3137–47

    Article  PubMed  CAS  Google Scholar 

  37. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 Sep 11–17; 364(9438): 937–52

    Article  PubMed  Google Scholar 

  38. Verdecchia P, Schillaci G, Borgioni C, et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hypertens 1995 Oct; 13(10): 1209–15

    Article  PubMed  CAS  Google Scholar 

  39. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992 Jan; 152(1): 56–64

    Article  PubMed  CAS  Google Scholar 

  40. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007 Mar 27; 115(12): 1544–50

    Article  PubMed  Google Scholar 

  41. Kronmal RA, Barzilay JI, Smith NL, et al. Mortality in pharmacologically treated older adults with diabetes: the Cardiovascular Health Study, 1989-2001 [abstract]. PLoS Med 2006 Oct; 3(10): e400

    Article  PubMed  Google Scholar 

  42. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008 Aug; 26(8): 1602–11

    Article  PubMed  CAS  Google Scholar 

  43. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359(9311): 1004–10

    Article  PubMed  CAS  Google Scholar 

  44. Verdecchia P, Reboldi G, Angeli F, et al. Prognostic value of lipoprotein fractions in essential hypertension. Blood Press 2004; 13(5): 295–303

    Article  PubMed  CAS  Google Scholar 

  45. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004 May; 43(5): 963–9

    Article  PubMed  CAS  Google Scholar 

  46. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25(9): 1751–62

    Article  PubMed  CAS  Google Scholar 

  47. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10–16; 366(9489): 895–906

    Article  PubMed  CAS  Google Scholar 

  48. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 Dec 4; 359(23): 2417–28

    Article  PubMed  CAS  Google Scholar 

  49. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359(9311): 995–1003

    Article  PubMed  CAS  Google Scholar 

  50. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007 Apr 28; 369(9571): 1431–9

    Article  PubMed  CAS  Google Scholar 

  51. McMurray JJ, Holman RR, Haffner SM, et al., NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362(16): 1477–90

    Article  PubMed  CAS  Google Scholar 

  52. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006 Feb 2; 354(5): 449–61

    Article  PubMed  Google Scholar 

  53. Suleiman M, Hammerman H, Boulos M, et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 2005 Feb 15; 111(6): 754–60

    Article  PubMed  CAS  Google Scholar 

  54. Meier JJ, Deifuss S, Klamann A, et al. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care 2005 Oct; 28(10): 2551–3

    Article  PubMed  Google Scholar 

  55. Meier JJ, Deifuss S, Klamann A, et al. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes 2003 Sep; 111(6): 344–50

    Article  PubMed  CAS  Google Scholar 

  56. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358(15): 1547–59

    Article  PubMed  CAS  Google Scholar 

  57. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008 Mar 25; 117(12): 1610–9

    Article  PubMed  Google Scholar 

  58. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997 May 24; 314(7093): 1512–5

    Article  PubMed  CAS  Google Scholar 

  59. Walter RE, Beiser A, Givelber RJ, et al. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003 Mar 15; 167(6): 911–6

    Article  PubMed  Google Scholar 

  60. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007 Apr; 191(2): 235–40

    Article  PubMed  CAS  Google Scholar 

  61. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002 Jul; 25(7): 1129–34

    Article  PubMed  Google Scholar 

  62. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004 May 4; 109(17): 2054–7

    Article  PubMed  CAS  Google Scholar 

  63. Ceriello A, Assaloni R, Da Ros R, et al. Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients. Diabetologia 2004 Sep; 47(9): 1535–40

    Article  PubMed  CAS  Google Scholar 

  64. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004 Feb 18; 43(4): 585–91

    Article  PubMed  Google Scholar 

  65. Kotliar C, Forcada P, Ferdinand KC. Noninvasive diagnosis of subclinical atherosclerosis in cardiometabolic syndrome: a call to action. J Cardiometab Syndr 2008 Winter; 3(1): 60–2

    Article  PubMed  Google Scholar 

  66. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004 Jul 1; 94(1): 20–4

    Article  PubMed  Google Scholar 

  67. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 Jun; 24(11): 987–1003

    Article  PubMed  CAS  Google Scholar 

  68. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) - endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006 Mar 21; 113(11): e463–654

    Article  PubMed  Google Scholar 

  69. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes; 10–11 February 1998, Miami, Florida. Diabetes Care 1998 Sep; 21 (9): 1551–9

  70. Scholte AJ, Schuijf JD, Kharagjitsingh AV, et al. Prevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetes. Heart 2008 Mar; 94(3): 290–5

    Article  PubMed  CAS  Google Scholar 

  71. Shaw LJ, Berman DS, Blumenthal RS, et al. Clinical imaging for prevention: directed strategies for improved detection of presymptomatic patients with undetected atherosclerosis - part I: clinical imaging for prevention. J Nucl Cardiol 2008 Jan-Feb; 15(1): e6–19

    Article  PubMed  Google Scholar 

  72. Wackers FJ, Chyun DA, Young LH, et al. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care 2007 Nov; 30(11): 2892–8

    Article  PubMed  Google Scholar 

  73. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21–27; 364(9435): 685–96

    Article  PubMed  CAS  Google Scholar 

  74. Maron DJ, Boden WE, O’Rourke RA, et al. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 2010 Mar 30; 55(13): 1348–58

    Article  PubMed  Google Scholar 

  75. Rutter MK, Nesto RW. The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease. Diab Vasc Dis Res 2010 Jan; 7(1): 69–72

    Article  PubMed  Google Scholar 

  76. Poli A, Marangoni F, Paoletti R, et al. Non-pharmacological control of plasma cholesterol levels. Nutr Metab Cardiovasc Dis 2008 Feb; 18(2): S1–16

    Article  PubMed  CAS  Google Scholar 

  77. Riccardi G, Rivellese AA, Giacco R. Role of glycemic index and glycemic load in the healthy state, in prediabetes, and in diabetes. Am J Clin Nutr 2008 Jan; 87(1): 269S–74S

    PubMed  CAS  Google Scholar 

  78. Mann JI, De Leeuw I, Hermansen K, et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004 Dec; 14(6): 373–94

    Article  PubMed  CAS  Google Scholar 

  79. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 1991 Dec; 34(12): 891–8

    Article  PubMed  CAS  Google Scholar 

  80. Knowler WC, Sartor G, Melander A, et al. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997 Jun; 40(6): 680–6

    Article  PubMed  CAS  Google Scholar 

  81. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 Feb 7; 346(6): 393–403

    Article  PubMed  CAS  Google Scholar 

  82. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 Jun 15; 359(9323): 2072–7

    Article  PubMed  CAS  Google Scholar 

  83. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006 Oct 12; 355(15): 1551–62

    Article  PubMed  Google Scholar 

  84. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 Jan 22; 355 (9200): 253–9

  85. Yusuf S, Sleight P, Pogue J, et al. Effects ofan angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342(3): 145–53

    Article  PubMed  CAS  Google Scholar 

  86. Gerstein HC, Bosch J, Pogue J, et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE study — microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Diabetes Care 1996 Nov; 19(11): 1225–8

    Article  PubMed  CAS  Google Scholar 

  87. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 Oct 9; 359(15): 1577–89

    Article  PubMed  CAS  Google Scholar 

  88. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366(9493): 1279–89

    Article  PubMed  CAS  Google Scholar 

  89. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002 Oct; 25(10): 1737–43

    Article  PubMed  CAS  Google Scholar 

  90. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005 Sep; 48(9): 1726–35

    Article  PubMed  CAS  Google Scholar 

  91. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007 Jul 5; 357(1): 28–38

    Article  PubMed  CAS  Google Scholar 

  92. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 Nov 11; 368(9548): 1660–72

    Article  PubMed  CAS  Google Scholar 

  93. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 Mar 3; 291(9): 1071–80

    Article  PubMed  CAS  Google Scholar 

  94. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005 Apr; 26(7): 650–61

    Article  PubMed  CAS  Google Scholar 

  95. Mellbin LG, Malmberg K, Norhammar A, et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008 Jan; 29(2): 166–76

    Article  PubMed  CAS  Google Scholar 

  96. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 Jan 12; 371(9607): 117–25

    Article  PubMed  CAS  Google Scholar 

  97. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 Oct 25; 112(17): 2735–52

    Article  PubMed  Google Scholar 

  98. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360(9349): 1903–13

    Article  PubMed  Google Scholar 

  99. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362(9395): 1527–35

    Article  PubMed  CAS  Google Scholar 

  100. Thomas F, Bean K, Pannier B, et al. Cardiovascular mortality in overweight subjects: the key role of associated risk factors. Hypertension 2005 Oct; 46(4): 654–9

    Article  PubMed  CAS  Google Scholar 

  101. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 Jan 20; 369(9557): 201–7

    Article  PubMed  CAS  Google Scholar 

  102. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345(12): 870–8

    Article  PubMed  CAS  Google Scholar 

  103. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345(12): 851–60

    Article  PubMed  CAS  Google Scholar 

  104. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345(12): 861–9

    Article  PubMed  CAS  Google Scholar 

  105. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 Aug 6; 106(6): 672–8

    Article  PubMed  CAS  Google Scholar 

  106. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004 May; 286(5): H1597–602

    Article  PubMed  CAS  Google Scholar 

  107. Kintscher U, Bramlage P, Paar WD, et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey: prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12–8

    Article  PubMed  CAS  Google Scholar 

  108. Vecchione C, Patrucco E, Marino G, et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3K-gamma. J Exp Med 2005 Apr 18; 201(8): 1217–28

    Article  PubMed  CAS  Google Scholar 

  109. Chiarelli F, Di Marzio D, Santilli F, et al. Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. Diabetes Care 2005 Jul; 28(7): 1690–7

    Article  PubMed  CAS  Google Scholar 

  110. Harris R, Donahue K, Rathore SS, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003 Feb 4; 138(3): 215–29

    PubMed  Google Scholar 

  111. Manson JE, Skerrett PJ, Greenland P, et al. The escalating pandemics of obesity and sedentary lifestyle: A call to action for clinicians. Arch Intern Med 2004 Feb 9; 164(3): 249–58

    Article  PubMed  Google Scholar 

  112. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007 Jan 2; 115(1): 114–26

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The present article was endorsed by the Italian Society of CV Prevention (SIPREC). This work has been partially supported by an unconditioned educational grant by Sanofi-Aventis, Italy.

Reviewers of the article: Maurizio Averna, Paolo Bellotti, Graziella Bruno, Emilio Chiurlia, Francesco Cosentino, Gaetano Crepaldi, Cristina Giannattasio, Giulio Nati, Mario Petretta, Paolo Pintus, Bianca Rocca.

Writing group of the English version of the article: Diana Chin, Marta Di Vavo, Alessandra Frattari, Giuliano Tocci.

Professor Chiariello died on 23 March 2010

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Massimo Volpe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volpe, M., Borghi, C., Perin, P.C. et al. Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Press Cardiovasc Prev 17, 73–102 (2010). https://doi.org/10.2165/11311830-000000000-00000

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11311830-000000000-00000

Keywords

Navigation